Tirabrutinib for CNS relapsed primary vitreoretinal lymphoma

被引：0
|
作者：
Yoshida, Nao [1 ]
Ureshino, Hiroshi [1 ]
Hiyama, Tomona [2 ]
Harada, Yosuke [2 ]
Nakatani, Suzuka [1 ]
Chishaki, Ren [1 ]
Edahiro, Taro [1 ]
Yoshida, Tetsumi [1 ]
Shindo, Takero [1 ]
Ichinohe, Tatsuo [1 ]
机构：
[1] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Hematol & Oncol, 1-2-3 Kasumi,Minami Ku, Hiroshima 7348553, Japan
[2] Hiroshima Univ, Grad Sch Biomed Sci, Dept Ophthalmol & Visual Sci, Hiroshima, Japan
来源：
ANNALS OF HEMATOLOGY | 2025年
关键词：
D O I：
10.1007/s00277-025-06284-3
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma
    Tun, Han W.
    Johnston, Patrick B.
    DeAngelis, Lisa M.
    Atherton, Pamela J.
    Pederson, Levi D.
    Koenig, Patricia A.
    Reeder, Craig B.
    Omuro, Antonio M. Padula
    Schiff, David
    O'Neill, Brian
    Pulido, Jose
    Jaeckle, Kurt A.
    Grommes, Christian
    Witzig, Thomas E.
    BLOOD, 2018, 132 (21) : 2240 - 2248
  • [2] Temozolomide for Relapsed Primary CNS Lymphoma
    Osmani, Asif Husain
    Masood, Nehal
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2012, 22 (09): : 594 - 595
  • [3] Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib
    Iizuka-Honma, Hiroko
    Takizawa, Haruko
    Mitsumori, Toru
    Okura, Hidehiro
    Ishii, Hisato
    Noguchi, Masaaki
    INTERNAL MEDICINE, 2023, 62 (03) : 459 - 463
  • [4] Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I/II study of tirabrutinib
    Arakawa, Yoshiki
    Narita, Yoshitaka
    Nagane, Motoo
    Mishima, Kazuhiko
    Terui, Yasuhito
    Yonezawa, Hajime
    Asai, Katsunori
    Fukuhara, Noriko
    Sugiyama, Kazuhiko
    Shinojima, Naoki
    Aoi, Arata
    Nishikawa, Ryo
    NEURO-ONCOLOGY ADVANCES, 2023, 5 (01)
  • [5] An investigator-initiated phase II trial of tirabrutinib in patients with relapsed or refractory secondary CNS lymphoma
    Munakata, W.
    Goto, H.
    Fukuhara, N.
    Nagai, H.
    Arima, H.
    Kato, K.
    Kurishita, K.
    Shuda, Y.
    Isomura, R.
    Ando, Y.
    Iwaki, N.
    Sadachi, R.
    Okita, N.
    Izutsu, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S1360 - S1360
  • [6] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Okita, Yoshiko
    Kano-Fujiwara, Rieko
    Nakatsuka, Shin-Ichi
    Honma, Keiichiro
    Kinoshita, Manabu
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [7] Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma
    Yoshiko Okita
    Rieko Kano-Fujiwara
    Shin-Ichi Nakatsuka
    Keiichiro Honma
    Manabu Kinoshita
    Experimental Hematology & Oncology, 10
  • [8] Primary vitreoretinal lymphoma
    Gilbert, Adrien
    Malaise, Denis
    Houillier, Caroline
    Soussain, Carole
    HEMATOLOGIE, 2024, 30 (04): : 245 - 263
  • [9] Primary vitreoretinal lymphoma
    Jaehne, D.
    Coupland, S. E.
    OPHTHALMOLOGE, 2018, 115 (04): : 343 - 356
  • [10] Primary vitreoretinal lymphoma
    Mulay, Kaustubh
    Narula, Ritesh
    Honavar, Santosh G.
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2015, 63 (03)
12345